PDCD1 and hepatocellular carcinoma: More recently, immune checkpoint inhibitors (ICIs), particularly antibodies targeting the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway, have been a major breakthrough in drug development for HCC [13].